Showing results out of
Judith Zaugg, Group Leader at EMBL Heidelberg, has been awarded an ERC Consolidator Grant of €2 million funded under the European Union’s Horizon Europe research and innovation programme. Over the next five years, the grant will enable her group to study cellular interactions in the human bone…
EMBL ANNOUNCEMENTSLAB MATTERS2022
embl-announcementslab-matters
A research collaboration used machine learning to map tumour molecular make-up, potentially paving way to more customised cancer treatment.
SCIENCE & TECHNOLOGY2021
sciencescience-technology
The EMBL Picture of the Week features a series of Jurkat T cells during different stages of the activation process.
SCIENCE & TECHNOLOGY2021
picture-of-the-weekscience-technology
A new method has the potential to boost international research efforts to find drugs that eradicate cancer at its source.
SCIENCE & TECHNOLOGY2021
sciencescience-technology
Studying cancers means also knowing what healthy cells look like. In this case, mesenchymal stromal cells (MSCs) from healthy bone marrow are a bit ‘loopy’.
SCIENCE & TECHNOLOGY2020
picture-of-the-weekscience-technology
The Heidelberg-based LeukoSyStem consortium investigates leukaemia stem cells in acute myeloid leukaemia. The German Federal Ministry of Education and Research financially supports this collaboration between Heidelberg University Hospital, HI-STEM gGmbH, the German Cancer Research Center and EMBL.
EMBL ANNOUNCEMENTS2020
embl-announcementsscience
Leukaemia – cancer of blood or bone marrow – is caused by mutations that allow defective blood cells to accumulate and displace healthy blood. To devise effective therapies it is crucial to know which mutations cause leukaemia and which cell type gives rise to leukaemic cells. Researchers from…
SCIENCE & TECHNOLOGY2008
sciencescience-technology
No results found